Neelapu SS, Locke FL, Bartlett NL, et al. Long-Term Follow-up ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). ASH 59th Annual Meeting & Exhibition, abstract 578.
Verlengde antistolling met verlaagde of volledige dosis DOAC bij VTE-patiënten met hoog recidiefrisico
apr 2025 | Benigne hematologie